Meeting
2021 ASCO Annual Meeting
Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial.
Authors
David R. Spigel
Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN
David R. Spigel , Corinne Faivre-Finn , Jhanelle Elaine Gray , David Vicente , David Planchard , Luis G. Paz-Ares , Johan F. Vansteenkiste , Marina Chiara Garassino , Rina Hui , Xavier Quantin , Andreas Rimner , Yi-Long Wu , Mustafa Ozguroglu , Ki Hyeong Lee , Terufumi Kato , Maike de Wit , Euan Macpherson , Michael Newton , Piruntha Thiyagarajah , Scott Joseph Antonia
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02125461
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 8511)
DOI
10.1200/JCO.2021.39.15_suppl.8511
Abstract #
8511
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A phase II study of durvalumab (MEDI4736) immediately after completion of chemoradiotherapy in unresectable stage III non–small cell lung cancer: TORG1937 (DATE study).
First Author: Shinji Nakamichi
Poster
2019 ASCO Annual Meeting
Gemstone-301: A phase III clinical trial of CS1001 as consolidation therapy in subjects with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who have not progressed after prior concurrent/sequential chemoradiotherapy (CRT).
First Author: Yi-Long Wu
Poster
2023 ASCO Annual Meeting
Phase 3 trial of durvalumab combined with domvanalimab following concurrent chemoradiotherapy (cCRT) in patients with unresectable stage III NSCLC (PACIFIC-8).
First Author: Mustafa Özgüroğlu
Poster
2023 ASCO Annual Meeting
A phase I-III platform study evaluating the safety and efficacy of multiple therapies in patients with biomarker-defined locally advanced, unresectable stage III non–small-cell lung cancer (NSCLC).
First Author: Luis G. Paz-Ares